That dose - 1.0 mg - is the glycemic-management dose of semaglutide, lower than the 2.4 mg weekly dose used for chronic weight management in the Wegovy formulation
A 2001 study (PMID: 11735244) found Ipamorelin partly counteracted glucocorticoid-induced bone formation loss in adult rats
Although it is well established that the endogenous GLP-1R system is essential for glycemic control, the specific GLP-1R population that mediates this effect is still a matter of debate
Eat smaller, more frequent meals with bland foods, stay well-hydrated, avoid high-fat or spicy foods, and follow the prescribed dose escalation schedule
The reason is clinical rather than commercial because safe GLP-1 management depends on ongoing follow-up, which is what membership provides
Possible side effects may include: Temporary water retention Mild increase in appetite (more common with GHRP-6) Tingling or numbness (due to GH release) Temporary injection site redness or swelling These effects are typically mild and resolve as your body adjusts to the therapy